Janssen CM-strategy: A Story of Multiple Platforms From R&D to Commercial

Presented by

Presented by Jeroen Geens, Engineering Technical Director at Janssen Research & Development & Dr Robin Meier at L.B Bohle

About this talk

After initial CM projects and successes for specific compounds in its commercial portfolio, Janssen defined in 2015 a vision to make continuous manufacturing the default platform for the development and launch of its entire portfolio or oral solid dosage forms. The Janssen vision has been translated in an end-to-end CM strategy and deployment plan, across R&D and Operations, demonstrating the need to have access to different CM technology platforms in order to achieve this goal. As part of this strategy, Janssen invested in its Mirror platform, redesigned the development approach in view of Continuous Manufacturing and built external partnerships. Important in successful deployment of the CM strategy is to continuously stick to the initial vision, despite the many challenges on the journey. While being pragmatic but selective in accepting outliers, not to be brought on CM, Janssen is shaping its CM-platform and network is not only for, but mainly through the R&D-portfolio.
Related topics:

More from this channel

Upcoming talks (39)
On-demand talks (353)
Subscribers (36601)
BioPharma Webinars aims to keep its global audience abreast of all developments in the areas of Drug Development, Manufacturing, Quality Assurance, Outsourcing and Regulatory Affairs, with only the highest quality webinars, presented by the most respected people, working with companies in Pharmaceutical, Biopharmaceutical, Biologics and Biotech Industry.